Payment overview · 2025
General Payments
$691.53
36 reported records · 16 companies
Healthcare provider profile · identity verified
John E Rathbun, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SURFSIDE BEACH, SC · NPI 1558345686
Verified facts
What the public records show
CMS Open Payments records show John E Rathbun, M.D. received $691.53 in general payments during 2025 across 36 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $165.60 | 23.9% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $100.64 | 14.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.15 | 9.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.73 | 8.2% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $46.22 | 6.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.27 | 6.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.09 | 5.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.50 | 4.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.21 | 3.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.17 | 2.9% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $19.80 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.63 | 2.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.40 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.96 | 2.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.72 | 2.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.44 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $691.53 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $165.60 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $78.26 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $46.22 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $45.94 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.27 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.81 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.67 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 91 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 225 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 39 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
225 | 56 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
44 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 599 | 192 |
| Losartan Potassium | Losartan Potassium | 548 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 458 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 458 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 447 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 411 | 119 |
| Quetiapine Fumarate | Quetiapine Fumarate | 300 | 75 |
| Montelukast Sodium | Montelukast Sodium | 260 | 86 |
| Furosemide | Furosemide | 255 | 93 |
| Lisinopril | Lisinopril | 243 | 71 |
| Simvastatin | Simvastatin | 233 | 62 |
| Farxiga | Dapagliflozin Propanediol | 225 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 211 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 78 |
| Tramadol Hcl | Tramadol Hcl | 200 | 70 |
| Famotidine | Famotidine | 199 | 64 |
| Alprazolam | Alprazolam | 187 | 53 |
| Metformin Hcl | Metformin Hcl | 177 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 47 |
| Allopurinol | Allopurinol | 166 | 43 |
| Potassium Chloride | Potassium Chloride | 162 | 67 |
| Gabapentin | Gabapentin | 149 | 50 |
| Donepezil Hcl | Donepezil Hcl | 144 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 49 |
| Omeprazole | Omeprazole | 133 | 49 |
| Atenolol | Atenolol | 127 | 34 |
| Carvedilol | Carvedilol | 127 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 43 |
| Meloxicam | Meloxicam | 112 | 39 |
| Prednisone | Prednisone | 109 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 101 | 80 |
| Azithromycin | Azithromycin | 99 | 78 |
| Terazosin Hcl | Terazosin Hcl | 98 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 27 |
| Eliquis | Apixaban | 91 | 28 |
| Cefuroxime | Cefuroxime Axetil | 88 | 69 |
| Propranolol Hcl | Propranolol Hcl | 88 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 85 | 65 |
| Ibandronate Sodium | Ibandronate Sodium | 83 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 23 |
| Glipizide | Glipizide | 82 | 23 |
| Ezetimibe | Ezetimibe | 78 | 23 |
| Sertraline Hcl | Sertraline Hcl | 78 | 25 |
| Xarelto | Rivaroxaban | 75 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 26 |
| Mounjaro | Tirzepatide | 73 | 11 |
| Ozempic | Semaglutide | 71 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 22 |
| Trazodone Hcl | Trazodone Hcl | 64 | 20 |
| Jardiance | Empagliflozin | 63 | 17 |
| Buspirone Hcl | Buspirone Hcl | 61 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 19 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 16 |
| Spironolactone | Spironolactone | 60 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 17 |
| Ibuprofen | Ibuprofen | 56 | 31 |
| Memantine Hcl | Memantine Hcl | 56 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 31 |
| Nitroglycerin | Nitroglycerin | 50 | 32 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 37 |
| Methylprednisolone | Methylprednisolone | 48 | 46 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 21 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 14 |
| Synthroid | Levothyroxine Sodium | 45 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 44 | 43 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 16 |
| Bupropion Xl | Bupropion Hcl | 41 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Ramipril | Ramipril | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 13 |
| Clotrimazole | Clotrimazole | 38 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 36 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | 24 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 11 |
| Kerendia | Finerenone | 33 | suppressed |
| Mupirocin | Mupirocin | 32 | 23 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 15 |
| Rybelsus | Semaglutide | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | 17 |
| Celecoxib | Celecoxib | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | 11 |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 25 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 17 |
| Glyxambi | Empagliflozin/Linagliptin | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Colchicine | Colchicine | 21 | 14 |
| Metronidazole | Metronidazole | 21 | 20 |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | 11 |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Torsemide | Torsemide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Diazepam | Diazepam | 19 | 11 |
| Fluconazole | Fluconazole | 19 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | 17 |
| Valsartan | Valsartan | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 16 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 13 | 12 |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $691.53 · 36 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ECC Solutions, ELIQUIS, FARXIGA, GVOKE HYPOPEN, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, YUPELRI | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error